<DOC>
	<DOCNO>NCT00002574</DOCNO>
	<brief_summary>Phase II trial study effectiveness homoharringtonine interferon alfa treat patient chronic myelogenous leukemia . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Interferon alfa may interfere growth cancer cell . Combining chemotherapy interferon alfa may kill cancer cell .</brief_summary>
	<brief_title>Homoharringtonine Interferon Alfa Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy homoharringtonine administer simultaneously interferon alpha achieve complete cytogenetic response patient chronic myelogenous leukemia chronic phase . OUTLINE : Single-Agent Chemotherapy plus Biological Response Modifier Therapy . Homoharringtonine , HH , NSC-141633 ; plus Interferon alfa ( Schering ) , IFN-A , NSC-377523 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Homoharringtonine</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Harringtonines</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Chronic myelogenous leukemia ( CML ) chronic phase Clonal evolution ( i.e. , presence clone Ph chromosome ) allow Ph chromosome variant complex Ph chromosome translocation consider disease acceleration Ineligible know therapy high efficacy priority Allogeneic bone marrow transplantation consider priority therapy CML patient match related donor No blastic phase CML ( 30 % blast peripheral blood bone marrow ) No accelerated phase CML , define follow : 15 % peripheral marrow blast 30 % blast promyelocytes 20 % peripheral marrow basophil Thrombocytopenia ( platelet le 100,000 ) unrelated therapy Documented extramedullary disease outside liver spleen PATIENT CHARACTERISTICS : Age : 15 Performance status : Zubrod 02 Life expectancy : Sufficient fully evaluate effect 2 course therapy Bilirubin great 2.0 mg/dL SGOT le 300 Creatinine less 2.0 mg/dL OR creatinine clearance least 60 mL/min No severe heart disease ( class III/IV ) No pregnant nursing woman Effective contraception require fertile woman PRIOR CONCURRENT THERAPY : No prior interferon alpha At least 2 week since antileukemic therapy , recovery required Patients receive hydroxyurea within past 2 week WBC great 50,000 may enter protocol discussion primary investigator</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2001</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
</DOC>